Literature DB >> 28089339

Discovery of a murine model of clinical PAH: Mission impossible?

Zhiyu Dai1, You-Yang Zhao2.   

Abstract

Pulmonary arterial hypertension (PAH) is a lung vascular disease characterized with a progressive increase of pulmonary vascular resistance and obliterative pulmonary vascular remodeling resulting in right heart failure and premature death. In this brief review, we document the recent advances in identifying genetically modified murine models of PH, with a focus on the recent discovery of the mouse model of Tie2 Cre-mediated deletion of prolyl hydroxylase 2, which exhibits progressive obliterative vascular remodeling, severe PAH, and right heart failure, thus recapitulating many of the features of clinical PAH. We will also discuss the translational potential of recent findings arising from experimental studies of murine PH models.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Animal model; Endothelium; Hypoxia inducible factor; Prolyl hydroxylases; Vascular remodeling

Mesh:

Substances:

Year:  2016        PMID: 28089339      PMCID: PMC5400690          DOI: 10.1016/j.tcm.2016.12.003

Source DB:  PubMed          Journal:  Trends Cardiovasc Med        ISSN: 1050-1738            Impact factor:   6.677


  53 in total

1.  Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line.

Authors:  R Constien; A Forde; B Liliensiek; H J Gröne; P Nawroth; G Hämmerling; B Arnold
Journal:  Genesis       Date:  2001-05       Impact factor: 2.487

Review 2.  A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects.

Authors:  Jose Gomez-Arroyo; Sheinei J Saleem; Shiro Mizuno; Aamer A Syed; Harm J Bogaard; Antonio Abbate; Laimute Taraseviciene-Stewart; Yon Sung; Donatas Kraskauskas; Daniela Farkas; Daniel H Conrad; Mark R Nicolls; Norbert F Voelkel
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-02-03       Impact factor: 5.464

3.  Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.

Authors:  P Jaakkola; D R Mole; Y M Tian; M I Wilson; J Gielbert; S J Gaskell; A von Kriegsheim; H F Hebestreit; M Mukherji; C J Schofield; P H Maxwell; C W Pugh; P J Ratcliffe
Journal:  Science       Date:  2001-04-05       Impact factor: 47.728

4.  Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice.

Authors:  You-Yang Zhao; Yang Liu; Radu-Virgil Stan; Lian Fan; Yusu Gu; Nancy Dalton; Po-Hsien Chu; Kirk Peterson; John Ross; Kenneth R Chien
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

5.  Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation.

Authors:  Barbara Girerd; David Montani; Florence Coulet; Benjamin Sztrymf; Azzeddine Yaici; Xavier Jaïs; David Tregouet; Abilio Reis; Valérie Drouin-Garraud; Alain Fraisse; Olivier Sitbon; Dermot S O'Callaghan; Gérald Simonneau; Florent Soubrier; Marc Humbert
Journal:  Am J Respir Crit Care Med       Date:  2010-01-07       Impact factor: 21.405

6.  Oxidative stress in severe pulmonary hypertension.

Authors:  Rebecca Bowers; Carlyne Cool; Robert C Murphy; Rubin M Tuder; Matthew W Hopken; Sonia C Flores; Norbert F Voelkel
Journal:  Am J Respir Crit Care Med       Date:  2003-12-30       Impact factor: 21.405

7.  Allosteric inhibition of hypoxia inducible factor-2 with small molecules.

Authors:  Thomas H Scheuermann; Qiming Li; He-Wen Ma; Jason Key; Lei Zhang; Rui Chen; Joseph A Garcia; Jacinth Naidoo; Jamie Longgood; Doug E Frantz; Uttam K Tambar; Kevin H Gardner; Richard K Bruick
Journal:  Nat Chem Biol       Date:  2013-02-24       Impact factor: 15.040

8.  HIF2α-arginase axis is essential for the development of pulmonary hypertension.

Authors:  Andrew S Cowburn; Alexi Crosby; David Macias; Cristina Branco; Renato D D R Colaço; Mark Southwood; Mark Toshner; Laura E Crotty Alexander; Nicholas W Morrell; Edwin R Chilvers; Randall S Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-18       Impact factor: 11.205

Review 9.  Pulmonary arterial hypertension: basis of sex differences in incidence and treatment response.

Authors:  K M Mair; A K Z Johansen; A F Wright; E Wallace; M R MacLean
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

10.  Selective inactivation of PTEN in smooth muscle cells synergizes with hypoxia to induce severe pulmonary hypertension.

Authors:  Henrick Horita; Seth B Furgeson; Allison Ostriker; Kyle A Olszewski; Timothy Sullivan; Leah R Villegas; Michelle Levine; Jane E Parr; Carlyne D Cool; Raphael A Nemenoff; Mary C M Weiser-Evans
Journal:  J Am Heart Assoc       Date:  2013-05-31       Impact factor: 5.501

View more
  7 in total

1.  CrossTalk opposing view: The mouse SuHx model is not a good model of pulmonary arterial hypertension.

Authors:  Sally H Vitali
Journal:  J Physiol       Date:  2018-11-29       Impact factor: 5.182

2.  CrossTalk proposal: The mouse SuHx model is a good model of pulmonary arterial hypertension.

Authors:  Krishna C Penumatsa; Rod R Warburton; Nicholas S Hill; Barry L Fanburg
Journal:  J Physiol       Date:  2018-11-29       Impact factor: 5.182

3.  Single-Cell RNA Sequencing Reveals Novel Genes Regulated by Hypoxia in the Lung Vasculature.

Authors:  Shelby Thomas; Sathiyanarayanan Manivannan; Vidu Garg; Brenda Lilly
Journal:  J Vasc Res       Date:  2022-03-16       Impact factor: 2.045

4.  Therapeutic Targeting of Vascular Remodeling and Right Heart Failure in Pulmonary Arterial Hypertension with a HIF-2α Inhibitor.

Authors:  Zhiyu Dai; Maggie M Zhu; Yi Peng; Narsa Machireddy; Colin E Evans; Roberto Machado; Xianming Zhang; You-Yang Zhao
Journal:  Am J Respir Crit Care Med       Date:  2018-12-01       Impact factor: 30.528

Review 5.  Sex differences in pulmonary arterial hypertension: role of infection and autoimmunity in the pathogenesis of disease.

Authors:  Kyle A Batton; Christopher O Austin; Katelyn A Bruno; Charles D Burger; Brian P Shapiro; DeLisa Fairweather
Journal:  Biol Sex Differ       Date:  2018-04-18       Impact factor: 5.027

6.  Suppression of BMP signaling by PHD2 deficiency in Pulmonary Arterial hypertension.

Authors:  Bin Liu; Dan Yi; Jiakai Pan; Jingbo Dai; Maggie M Zhu; You-Yang Zhao; S Paul Oh; Michael B Fallon; Zhiyu Dai
Journal:  Pulm Circ       Date:  2022-03-23       Impact factor: 2.886

7.  Endothelial Autocrine Signaling through CXCL12/CXCR4/FoxM1 Axis Contributes to Severe Pulmonary Arterial Hypertension.

Authors:  Dan Yi; Bin Liu; Ting Wang; Qi Liao; Maggie M Zhu; You-Yang Zhao; Zhiyu Dai
Journal:  Int J Mol Sci       Date:  2021-03-20       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.